AngioDynamics, Inc. (NASDAQ:ANGO) Shares Acquired by Cwm LLC

Cwm LLC lifted its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 981.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,732 shares of the medical instruments supplier’s stock after buying an additional 8,832 shares during the period. Cwm LLC’s holdings in AngioDynamics were worth $76,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quarry LP lifted its stake in shares of AngioDynamics by 75.1% during the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 2,594 shares during the period. Mackenzie Financial Corp acquired a new stake in shares of AngioDynamics during the second quarter worth $80,000. AE Wealth Management LLC acquired a new stake in shares of AngioDynamics during the second quarter worth $87,000. State Board of Administration of Florida Retirement System lifted its stake in shares of AngioDynamics by 44.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier’s stock worth $92,000 after buying an additional 4,780 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of AngioDynamics during the third quarter worth $103,000. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on ANGO. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of AngioDynamics in a report on Friday, October 4th. Canaccord Genuity Group reduced their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a report on Friday, October 4th.

AngioDynamics Stock Performance

ANGO opened at $6.73 on Friday. AngioDynamics, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $8.25. The company has a fifty day moving average of $7.15 and a two-hundred day moving average of $6.68. The stock has a market capitalization of $269.57 million, a price-to-earnings ratio of -1.39 and a beta of 0.65.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The company had revenue of $67.50 million during the quarter, compared to analysts’ expectations of $67.93 million. During the same quarter in the previous year, the company earned ($0.12) earnings per share. The firm’s revenue for the quarter was down 14.2% on a year-over-year basis. On average, equities research analysts forecast that AngioDynamics, Inc. will post -0.41 earnings per share for the current year.

Insider Transactions at AngioDynamics

In related news, CEO James C. Clemmer bought 20,000 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was acquired at an average price of $6.03 per share, with a total value of $120,600.00. Following the completion of the purchase, the chief executive officer now directly owns 681,582 shares of the company’s stock, valued at approximately $4,109,939.46. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders purchased 22,568 shares of company stock valued at $135,847 over the last 90 days. Corporate insiders own 5.10% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.